Oyster Point Pharma, Inc.
OYSTDrugs in Pipeline
7
Phase 3 Programs
3
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
OC-01 (varenicline) nasal spray
Dry Eye Disease (DED)
OC-01 Low Dose, 0.12 mg/mL
Long Term Follow up Dry Eye Disease
Varenicline Tartrate Nasal Spray
Dry Eye Disease
0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL)
Dry Eye Disease
OC-01 (varenicline) nasal spray 1.2 mg/ml
Neurotrophic Keratopathy
OC-02 (simpinicline) nasal spray
Dry Eye Disease
OC-01 0.1% 0.6 mg/ml
Dry Eye Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
OC-01 (varenicline) nasal spray | Phase 3 | Dry Eye Disease (DED) | - | - |
OC-01 Low Dose, 0.12 mg/mL | Phase 3 | Long Term Follow up Dry Eye Disease | - | - |
Varenicline Tartrate Nasal Spray | Phase 3 | Dry Eye Disease | - | - |
0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL) | Phase 2 | Dry Eye Disease | - | - |
OC-01 (varenicline) nasal spray 1.2 mg/ml | Phase 2 | Neurotrophic Keratopathy | - | - |
OC-02 (simpinicline) nasal spray | Phase 2 | Dry Eye Disease | - | - |
OC-01 0.1% 0.6 mg/ml | Phase 2 | Dry Eye Disease | - | - |
Frequently asked questions
What is in Oyster Point Pharma, Inc.'s drug pipeline?→
CatalystAlert tracks 7 drug candidates in Oyster Point Pharma, Inc.'s (OYST) pipeline across Phase 3, Phase 2. Its lead program is OC-01 (varenicline) nasal spray (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Oyster Point Pharma, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Oyster Point Pharma, Inc. (OYST) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track OYST biotech catalysts?→
Add OYST to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Oyster Point Pharma, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.